<DOC>
	<DOC>NCT01582945</DOC>
	<brief_summary>Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD). This is an open-label study (pilot).</brief_summary>
	<brief_title>Ketamine Infusion for Treatment-resistant Major Depressive Disorder</brief_title>
	<detailed_description>Patients will undergo two weeks of prospective observation, they will then receive ketamine IV 0.5mg/kg over 45 minutes as augmentation of their ongoing antidepressant regimen; after three infusions this dose will be increased increase to 0.75 mg/kg in non-responders. The schedule of administration will be twice a week for 3 weeks. After this phase, the patient will be followed with assessments every two weeks for three months. Total duration of the study is 5 months.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Outpatients with severe treatmentresistant MDD Currently depressed Currently under regular psychiatric care On an aggressive antidepressant regimen, stable for 4 weeks No history of other major psychiatric illnesses, including bipolar disorder No history of psychosis No history of drug abuse No major medical illness or unstable medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Treatment resistant</keyword>
	<keyword>suicidal ideation</keyword>
	<keyword>major depressive disorder</keyword>
</DOC>